www.asiabiotech.com People

Singapore Welcomes Sir David Lane!

ingapore has successfully wooed a top-notch cancer researcher to head the Institute of Molecular and Cell Biology (IMCB), a member of the country’s main life sciences Sbody, the Agency for Science, Techology and Research (A*Star). Professor Sir David Lane hails from Scotland’s University of Dundee, a world-renowned institution highly acclaimed for its biomedical and life sciences research. Practically a household name in the field of cancer, Prof. Lane is best known for his 1979 breakthrough discovery of the landmark cancer gene — the p53 cancer gene. Mutations of this tumor suppressor gene are found in more than half of all human cancers. This finding has pointed the way for other cancer researchers to understand and manipulate the cellular processes in cancer. As of August 2004, Prof. Lane officially assumes the role of executive director of IMCB. His stint in Singapore is a two-year sabbatical, during which he will maintain his links in Britain. Prof. Lane sees this new appointment as a research opportunity to translate basic biological science into new technologies and new medicines in an integrated environment.

More on Professor Lane… “It is a mark of David Lane’s distinction that he has been asked to become IMCB’s executive Professor Lane founded biopharmaceutical director. He has long been one of the most company Cyclacel in September 1996. Until May of 2004, he was the company’s Chief respected scientists and is a valued member of Scientific Officer and continues to Chair the the scientific executive board at Cancer Scientific Advisory Board. Research UK. Our close association with him Professor Lane is Professor of Molecular will continue both in Singapore and Dundee.” Oncology and Director of the CRC Cell Transformation Research Group in the Professor Robert Souhami Department of Biochemistry at the University of Dundee. He has previously held the positions Executive Director of Clinical Affairs of Principal Scientist at the Imperial Cancer Cancer Research, UK (World’s largest independent organization Research Fund and Lecturer in Biochemistry at dedicated to cancer research) Imperial College.

APBN • Vol. 9 • No. 5 • 2005 191 www.asiabiotech.com People

Professor Lane holds a PhD from University College London, and did his postdoctoral work at Imperial Cancer Research Fund in London and at Cold Spring Harbor Laboratory in New York. He is a Fellow of the Royal Society and a member of the European Molecular Biology Organization. In 2000, Prof. Lane was knighted for his contributions to cancer research, and was named by Science magazine as the world’s seventh most-cited scientist. He has won numerous international awards, including the Paul Ehrlich Prize, the Joseph Steiner Prize, the CR Brupbacher Foundation Prize, the Medal of the Swedish Society of Oncology, the Yvette Mayent Prize, the Mayenberg Preis, the Silvanus Thompson Medal, the Medal of the Society of Chemical Industry and has been named a Howard Hughes Scholar. He has authored approximately 250 publications and patents.

About Cyclacel Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel’s discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, RNAi functional genomics, chemogenomics and clinical biomarker technologies to deliver new drugs. The company has nine research and development programs underway. Most advanced is CYC202, an oral Cyclin Dependent Kinase (CDK) inhibitor, in Phase II trials for lung cancer and hematological malignancies. CYC202 has completed Phase I trials and is also being explored for use in glomerulonephritis, an inflammatory disease associated with kidney cell proliferation. CYC682, an oral nucleoside analogue, in Phase Ib trials was shown in preclinical tests to have superior efficacy to gemcitabine. Cyclacel has entered into corporate alliances with AstraZeneca, CV Therapeutics, GlaxoSmithKline, Lorus and Sankyo, all in the oncology field. Cyclacel is the first European university spin-out company to have raised more than US$100 million in private equity.

Contact Details: Cyclacel Limited Address: James Lindsay Place, Dundee Technopole Dundee DD1 5JJ, United Kingdom Tel: +44 1382 206 062 Fax: +44 1382 206 067 Email: [email protected] URL: www.cyclacel.com

192 APBN • Vol. 9 • No. 5 • 2005